Reducing Cost and Risk in Lentiviral Manufacturing with the LV Edge Packaging System

In the manufacturing of lentivirus vectors for cell and gene therapy applications, GMP-grade plasmids account for a significant proportion of the raw material costs. The procurement of these plasmids also introduces supply chain complexity, which can impact both timelines and product variability.  

In this GEN webinar, Mark Stockdale discusses the challenges and bottlenecks associated with lentiviral manufacture, and introduces the LV Edge Packaging System, which minimizes GMP plasmid cost, process complexity, and supply chain risk by stably integrating viral genes into the host cell.  

Key topics covered in the webinar include:      
How the LV Edge Packaging System achieves greater than 1E8 TU/mL titers and enables tunable transgene expression in transduced cells;
How a clonal, suspension-adapted packaging cell line reduces the need for GMP plasmids;      
How model-guided DNA design can optimize transgene expression and lentiviral titer;      
How to access the system to reduce cost and risk in the design and manufacture of novel therapeutics. ‍